Posting fresh info about MS, for people with MS and their supporters

Newly Published Data Show Copaxone Promoted Remyelination of Damaged Axons

• The purpose of this study was to examine the effect of glatiramer acetate on oligodendrogenesis (the formation of myelin-producing glial cells in the central nervous system) and myelin formation in damaged nerve cells in mice
• The mice were subjected to lysolecithin-induced demyelination of the spinal cord, then treated daily for seven days with a 2mg injection of glatiramer acetate
• After only three days, mice treated with glatiramer acetate experienced an increase in insulin-like growth factor-1 (IGF-1)
• After seven days, and throughout the 28-day trial, resultant myelination was higher in mice treated with glatiramer acetate compared to control group
• These results suggest glatiramer acetate may promote oligodendrogenesis and myelin formation through elevation of neurotrophic growth factors that foster myelin repair, and that the long-term benefits from patients treated with glatiramer acetate may be, in part, due to remyelination
• The neuroprotective potential of glatiramer acetate has been previously suggested in pre-clinical and clinical trials of relapsing-remitting multiple sclerosis (RRMS)

View full article here: http://www.mscare.org/cmsc/Informs-Glatiramer-Acetate-data.html

• BROWSE / IN TIMELINE
• « Teva Sues Mylan Over MS Drug Copaxone
• » FDA delays ruling on Acorda’s MS drug until 1/2010

• BROWSE / IN Current Therapies
• « Teva Sues Mylan Over MS Drug Copaxone